Kyowa to Skip May Listing for Enbrel Biosimilar, Codeveloper YL Biologics to Move Ahead

April 11, 2019
Kyowa Pharmaceutical Industry has decided to take a pass on the upcoming May listing of its Enbrel (etanercept) biosimilar, one of the two follow-on biologics approved in March for Pfizer’s major rheumatoid arthritis drug. YL Biologics, a codeveloper who gained...read more